2024 EAACI conference: Celldex presents Phase 2 study data showing barzolvolimab significantly improves angioedema in chronic spontaneous urticaria patients, meeting primary and secondary endpoints.

Celldex Therapeutics presents data at EAACI 2024 showing barzolvolimab, in a Phase 2 study, achieves profound improvements in angioedema at 12 weeks in patients with chronic spontaneous urticaria. Angioedema, a debilitating CSU symptom, significantly impacts quality of life. The improvement observed in the study met its primary and secondary endpoints.